ACR 2022 Tweet by Dr. Antoni Chan
TweetRelated Content
The NEPTUNUS-1 and NEPTUNUS-2 trials have showed that monthly ianalumab is superior of placebo at improving Sjögren’s disease activity at week 48, even though there was no significant ESSDAI response or in the change in SSSD or ESSPRI symptom scores.
Drs. Yuz Yusof and Xavier Mariette discuss abstract OP0126 presented at the 2026 EULAR meeting in London
Nipocalimab, a neonatal Fc receptor blocker that reduces circulating IgG and autoantibodies, was shown to be effective in a phase 2 trial in patients with severe Sjögren's disease.
